Climb Bio, Inc 10-Q for FY2026 Q3
Climb Bio, Inc. (CLYM)
10-Q
2026-11-05
For: 2026-09-30
View Original
Added on
November 05, 2026
About this 10-Q
Climb Bio, Inc filed this 10-Q on November 5, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
Budoprutug produced deeper peripheral B-cell depletion at 600 mg, with mean suppression of 98% at Week 4. Climb Bio, Inc. reported $227.6 million in cash and marketable securities on September 30, 2026, funding operations into the second half of 2028. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Net loss
- $14.57M
- compared with a net loss of $12.89M a year earlier
- Diluted EPS
- -$0.18
- compared with -$0.19 a year earlier